Astellas Wins U.S. FDA Advisory Panel Backing For Mirabegron
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma won support of a U.S. FDA advisory panel for its daily drug for treating overactive bladders despite a cautionary report by the agency’s own staff.